Form 4: Axsome Therapeutics Director Receives RSU Grant

Director Susan Mahony was granted 1,721 restricted stock units as part of Axsome Therapeutics' equity compensation program.

Summary

• Director Susan Mahony received a grant of 1,721 restricted stock units (RSUs) on June 5, 2026.
• Each RSU represents a contingent right to receive one share of Axsome Therapeutics common stock.
• The grant is subject to a one-year vesting schedule, fully vesting on June 5, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in minor potential future dilution for existing shareholders.

Risks

• Standard equity market risks associated with holding company stock.

Future Outlook

The RSUs are scheduled to vest in full on the one-year anniversary of the grant date, June 5, 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant size and one-year cliff vesting schedule are consistent with typical director compensation packages for mid-cap biopharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the equity grant.

Next Steps

• Vesting of the 1,721 RSUs on June 5, 2027.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Transaction, Equity Compensation, Director Compensation